$CMPX
Compass Therapeutics, Inc.

2022 Q1 Form 10-Q Financial Statement

#000095017022008244 Filed on May 09, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.767M $2.635M
YoY Change 5.01% 16.59%
% of Gross Profit
Research & Development $4.415M $4.704M
YoY Change -6.14% 31.73%
% of Gross Profit
Depreciation & Amortization $200.0K $200.0K
YoY Change 0.0% -60.0%
% of Gross Profit
Operating Expenses $7.182M $7.339M
YoY Change -2.14% 25.86%
Operating Profit -$7.182M -$7.339M
YoY Change -2.14% 25.86%
Interest Expense $0.00 $142.0K
YoY Change -100.0% -48.55%
% of Operating Profit
Other Income/Expense, Net $20.00K -$83.00K
YoY Change -124.1% -85.05%
Pretax Income -$7.162M -$7.422M
YoY Change -3.5% 16.22%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$7.162M -$7.422M
YoY Change -3.5% 15.93%
Net Earnings / Revenue
Basic Earnings Per Share -$0.07
Diluted Earnings Per Share -$71.01K -$144.6K
COMMON SHARES
Basic Shares Outstanding 101.3M 52.11M
Diluted Shares Outstanding

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $136.4M $39.70M
YoY Change 243.57%
Cash & Equivalents $136.4M $39.85M
Short-Term Investments
Other Short-Term Assets $3.904M $1.952M
YoY Change 100.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $140.3M $41.65M
YoY Change 236.84%
LONG-TERM ASSETS
Property, Plant & Equipment $2.142M $6.080M
YoY Change -64.77%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $320.0K $471.0K
YoY Change -32.06%
Total Long-Term Assets $6.281M $6.551M
YoY Change -4.12%
TOTAL ASSETS
Total Short-Term Assets $140.3M $41.65M
Total Long-Term Assets $6.281M $6.551M
Total Assets $146.6M $48.20M
YoY Change 204.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $257.0K $1.061M
YoY Change -75.78%
Accrued Expenses $8.050M $1.290M
YoY Change 524.03%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $7.474M
YoY Change
Total Short-Term Liabilities $9.334M $10.85M
YoY Change -13.97%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $2.740M $3.877M
YoY Change -29.33%
Total Long-Term Liabilities $2.740M $3.877M
YoY Change -29.33%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.334M $10.85M
Total Long-Term Liabilities $2.740M $3.877M
Total Liabilities $12.07M $14.73M
YoY Change -18.01%
SHAREHOLDERS EQUITY
Retained Earnings -$240.8M
YoY Change
Common Stock $375.2M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $134.5M $33.47M
YoY Change
Total Liabilities & Shareholders Equity $146.6M $48.20M
YoY Change 204.09%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$7.162M -$7.422M
YoY Change -3.5% 15.93%
Depreciation, Depletion And Amortization $200.0K $200.0K
YoY Change 0.0% -60.0%
Cash From Operating Activities -$7.942M -$5.605M
YoY Change 41.69% -27.78%
INVESTING ACTIVITIES
Capital Expenditures $194.0K $128.0K
YoY Change 51.56% 966.67%
Acquisitions
YoY Change
Other Investing Activities $1.000K $115.0K
YoY Change -99.13%
Cash From Investing Activities -$193.0K -$13.00K
YoY Change 1384.62% 8.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 -1.875M
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -7.942M -5.605M
Cash From Investing Activities -193.0K -13.00K
Cash From Financing Activities 0.000 -1.875M
Net Change In Cash -8.135M -7.493M
YoY Change 8.57% -3.6%
FREE CASH FLOW
Cash From Operating Activities -$7.942M -$5.605M
Capital Expenditures $194.0K $128.0K
Free Cash Flow -$8.136M -$5.733M
YoY Change 41.92% -26.24%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001738021
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Entity File Number
EntityFileNumber
001-39696
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
COMPASS THERAPEUTICS, INC.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-4876496
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
80 Guest St.
CY2022Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 601
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02135
CY2022Q1 dei City Area Code
CityAreaCode
617
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
500-8099
CY2022Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
CY2022Q1 dei Trading Symbol
TradingSymbol
CMPX
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
101283924
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2243000
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
4415000
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Assets Current
AssetsCurrent
147105000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2142000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
136379000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
144514000
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3904000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2591000
CY2022Q1 us-gaap Assets Current
AssetsCurrent
140283000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8050000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8775000
CY2021Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
4704000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2767000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1027000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
989000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
9334000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10631000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2740000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3048000
CY2022Q1 us-gaap Liabilities
Liabilities
12074000
CY2021Q4 us-gaap Liabilities
Liabilities
13679000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2635000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3819000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4089000
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
320000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
320000
CY2022Q1 us-gaap Assets
Assets
146564000
CY2021Q4 us-gaap Assets
Assets
153757000
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
257000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
867000
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
101286000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
101303000
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
100905000
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
100832000
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
10000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
10000
CY2022Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
375231000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
373657000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-240751000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-233589000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
134490000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-7339000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
7182000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-7162000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-7422000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
140078000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
146564000
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
165000
CY2021Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
157000
CY2022Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
153757000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
7339000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-7182000
CY2022Q1 cmpx Net Loss
NetLoss
-7162000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
134490000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
39945000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
948000
CY2021Q1 cmpx Net Loss
NetLoss
-7422000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
33471000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
20000
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-83000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7162000
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7422000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-7162000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-7422000
CY2022Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.07
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.14
CY2022Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
100858000
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
51313000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
140078000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1574000
CY2021Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
44000
CY2022Q1 cmpx Non Cash Interest Expense
NonCashInterestExpense
0
CY2021Q1 cmpx Non Cash Interest Expense
NonCashInterestExpense
15000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1574000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
948000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
270000
CY2021Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
256000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1313000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1173000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-611000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
0
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-595000
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-442000
CY2022Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-270000
CY2021Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-246000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7942000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5605000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
194000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
128000
CY2022Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
1000
CY2021Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
115000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-193000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-13000
CY2022Q1 us-gaap Repayments Of Debt
RepaymentsOfDebt
0
CY2021Q1 us-gaap Repayments Of Debt
RepaymentsOfDebt
1875000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1875000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-8135000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7493000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
144514000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
47339000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
136379000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
39846000
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
0
CY2021Q1 us-gaap Interest Paid Net
InterestPaidNet
137000
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
57000
CY2021Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
161000
CY2022Q1 cmpx Noncash Or Part Noncash Right Of Use Asset Acquired Through Operating Leases
NoncashOrPartNoncashRightOfUseAssetAcquiredThroughOperatingLeases
0
CY2021Q1 cmpx Noncash Or Part Noncash Right Of Use Asset Acquired Through Operating Leases
NoncashOrPartNoncashRightOfUseAssetAcquiredThroughOperatingLeases
5148000
CY2022Q1 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2018-03-20
CY2022Q1 us-gaap Proceeds From Sale Of Available For Sale Securities Equity
ProceedsFromSaleOfAvailableForSaleSecuritiesEquity
329000000.0
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
136400000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8775000
CY2022Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7318000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7269000
CY2022Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5176000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5026000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2142000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2243000
CY2022Q1 us-gaap Depreciation
Depreciation
200000
CY2021Q1 us-gaap Depreciation
Depreciation
200000
CY2022Q1 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
490000
CY2021Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1601000
CY2022Q1 cmpx Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
1465000
CY2021Q4 cmpx Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
704000
CY2022Q1 cmpx Accrued Milestone Current
AccruedMilestoneCurrent
6000000
CY2021Q4 cmpx Accrued Milestone Current
AccruedMilestoneCurrent
6000000
CY2022Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
95000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
470000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8050000
CY2022Q1 cmpx Number Of Operating Lease
NumberOfOperatingLease
1
CY2022Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P4Y5M
CY2022Q1 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.0625
CY2022Q1 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P3Y2M
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
875000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1345000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1379000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
543000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
4142000
CY2022Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
375000
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
3767000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1027000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2740000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1574000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
948000
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
14000000.0
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.77
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
9200000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.58
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
20000
CY2021Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
15000
CY2022Q1 us-gaap Interest Expense
InterestExpense
0
CY2021Q1 us-gaap Interest Expense
InterestExpense
142000
CY2022Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
CY2021Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
44000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
20000
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-83000

Files In Submission

Name View Source Status
0000950170-22-008244-index-headers.html Edgar Link pending
0000950170-22-008244-index.html Edgar Link pending
0000950170-22-008244.txt Edgar Link pending
0000950170-22-008244-xbrl.zip Edgar Link pending
cmpx-20220331.htm Edgar Link pending
cmpx-20220331.xsd Edgar Link pending
cmpx-20220331_cal.xml Edgar Link unprocessable
cmpx-20220331_def.xml Edgar Link unprocessable
cmpx-20220331_htm.xml Edgar Link completed
cmpx-20220331_lab.xml Edgar Link unprocessable
cmpx-20220331_pre.xml Edgar Link unprocessable
cmpx-ex31_1.htm Edgar Link pending
cmpx-ex31_2.htm Edgar Link pending
cmpx-ex32_1.htm Edgar Link pending
cmpx-ex32_2.htm Edgar Link pending
cmpx-ex99_1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
img119605530_0.jpg Edgar Link pending
img119605530_1.jpg Edgar Link pending
img174977587_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending